QPPV.COM KNOWLEDGE ASSESSMENT

Rituximab: Classification, Mechanism and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Rituximab: Classification, History, Mechanism of Action and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A pharmacovigilance team compares serious infection reports between a reference rituximab and a biosimilar. Which analytical approach is most appropriate?

Compare crude case counts without considering exposure Adjust or stratify for indication, regimen, route, brand, treatment line, prior exposure and reporting differences where possible Assume any numerical imbalance demonstrates a product-quality defect Pool all products and remove brand information to avoid bias

Question 2 of 10 Which information is most important when evaluating delayed-onset neutropenia after rituximab?

Only whether the patient had an infusion reaction Serial blood counts, timing after the last dose, marrow disease, infection and concomitant medicines Only the rituximab brand name Whether the patient had a positive vaccine response

Question 3 of 10 Which feature best explains why rituximab is classified as a type I anti-CD20 antibody?

It binds only soluble CD20 released into plasma It promotes CD20 redistribution into membrane microdomains and is associated with strong complement engagement It lacks an Fc region and acts exclusively through intracellular signalling It selectively targets terminally differentiated plasma cells

Question 4 of 10 Why must the intravenous and subcutaneous presentations be treated as distinct medication-use risks?

They contain unrelated active substances They differ in route, volume, eligibility requirements and administration controls The subcutaneous product is automatically interchangeable with intravenous administration Route differences affect only product packaging, not clinical safety

Question 5 of 10 Why may pre-existing antibody concentrations persist immediately after rituximab treatment?

Rituximab directly increases plasma-cell production Terminally differentiated plasma cells usually lack CD20 and are not directly depleted CD20 is expressed only on malignant B cells Complement activation prevents antibody catabolism

Question 6 of 10 A patient develops fever, rigors and hypotension during the first intravenous infusion. Which interpretation is most appropriate initially?

The event must be an IgE-mediated allergy because it occurred on first exposure The event may reflect cytokine release and complement activation associated with rapid target-cell and effector interaction The event is most likely delayed hypogammaglobulinaemia The event is unrelated to infusion rate or tumour burden

Question 7 of 10 Which finding most clearly distinguishes clinically important hypogammaglobulinaemia from an isolated laboratory abnormality?

A single low immunoglobulin result with no clinical information Persistently reduced immunoglobulins accompanied by recurrent or severe infections A transient increase in peripheral B-cell counts A normal baseline immunoglobulin concentration before the first dose

Question 8 of 10 Why can profound depletion of peripheral B cells fail to demonstrate complete depletion in a patient?

Peripheral blood counts directly measure all tissue B cells Rituximab is unable to bind CD20 in blood Tissue compartments differ in antibody penetration, target phenotype and effector-cell access B cells cannot repopulate outside the bloodstream

Question 9 of 10 Which feature makes tumour lysis syndrome particularly relevant in some rituximab-treated oncology patients?

It results from destruction of a large malignant-cell burden and release of intracellular contents It is an unavoidable consequence of any B-cell depletion It occurs only after subcutaneous administration It is caused primarily by depletion of haematopoietic stem cells

Question 10 of 10 Which B-cell population is generally spared directly by rituximab, thereby allowing eventual B-cell compartment regeneration?

Mature memory B cells Many malignant B cells Haematopoietic stem cells Late pre-B cells

QPPV.com

Rituximab: Classification, Mechanism and Pharmacovigilance Knowledge Assessment

Cookie Settings